급성 간헐성 포르피린증 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)

Acute Intermittent Porphyria Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

US $ 5,795 ￦ 8,600,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795 ￦ 13,053,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795 ￦ 17,506,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

급성 간헐성 포르피린증 시장 - 연구 범위

TMR의 조사 보고서 "세계 급성 간헐성 포르피린증 시장"은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준 연도 및 2034년을 예측 연도로 간주하여 2018년부터 2034년까지 전 세계 급성 간헐성 포르피린증 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 급성 간헐성 포르피린증 시장의 연평균 복합 성장률(CAGR%)도 제시합니다.

이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사는 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체와의 인터뷰를 통해 수행되었으며, 2차 조사는 급성 간헐성 포르피린증 시장을 이해하기 위해 주요 기업의 제품 자료, 연례 보고서, 보도 자료 및 관련 문서를 참조했습니다, 관련 문서를 참고했습니다.

시장 현황
2023년 시장 규모	460만 달러
2034년 시장 가치	710만 달러
CAGR	3.9%

이 보고서는 세계 급성 간헐성 포르피린증 시장의 경쟁 환경에 대해 자세히 연구하고 있습니다. 세계 급성 간헐성 포르피린증 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 특성으로 프로파일링되었습니다. 기업 개요, 재무 상태, 최근 동향 및 SWOT는 이 보고서에서 다루는 세계 급성 간헐성 포르피린증 시장의 기업 속성입니다.

목차

제1장 서문

제2장 조사의 전제조건과 조사 방법

제3장 주요 요약 : 시장

제4장 시장 개요

• 서론
• 시장 개요
• 시장 역학
• 시장 분석과 예측, 2020-2034년

제5장 주요 인사이트

• 파이프라인 분석
• 주요 제품 및 브랜드 분석
• 주요 M&A
• COVID-19 팬데믹의 산업에 대한 영향

제6장 세계 시장 분석과 예측 : 진단별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 매출 예측 : 진단별, 2020년-2034년
  • 혈액검사
  • 요검사
  • DNA 검사
  • 혈청 검사
• 시장의 매력 분석 : 진단별

제7장 세계 시장 분석과 예측 : 치료별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 매출 예측 : 치료제별, 2020년-2034년
  • Gonadotropin-Releasing Hormone Analogues
  • Prophylactic Hematin Infusions
• 시장의 매력 분석 : 치료별

제8장 세계 시장 분석과 예측 : 최종사용자별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 매출 예측 : 최종사용자별, 2020년-2034년
  • 병원
  • 클리닉
  • 연구센터
• 시장의 매력 분석 : 최종사용자별

제9장 세계 시장 분석과 예측 : 지역별

• 주요 조사 결과
• 시장 매출 예측 : 지역별, 2020-2034
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 시장의 매력 분석 : 지역별

제10장 북미 시장 분석과 예측

제11장 유럽 시장 분석과 예측

제12장 아시아태평양 시장 분석과 예측

제13장 라틴아메리카 시장 분석과 전망

제14장 중동 및 아프리카 시장 분석과 전망

제15장 경쟁 구도

• 시장 경쟁 매트릭스(기업 Tier별·기업 규모별)
• 시장 점유율 분석 : 기업별(2023년)
• 기업 개요
  • Alnylam Pharmaceuticals, Inc.
  • Clinuvel Pharmaceuticals Ltd.
  • BioMarin Pharmaceutical Inc.
  • Recordati
  • Quest Diagnostics
  • Invitae Corp.
  • Laboratory Corporation of America Holdings(Labcorp)
  • ARUP Laboratories

LSH

영문 목차

영문목차

Acute Intermittent Porphyria Market - Scope of Report

TMR's report on the global acute intermittent porphyria market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global acute intermittent porphyria market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute intermittent porphyria market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the acute intermittent porphyria market.

Market Snapshot
Market Value in 2023	US$ 4.6 Mn
Market Value in 2034	US$ 7.1 Mn
CAGR	3.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global acute intermittent porphyria market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global acute intermittent porphyria market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global acute intermittent porphyria market.

The report delves into the competitive landscape of the global acute intermittent porphyria market. Key players operating in the global acute intermittent porphyria market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global acute intermittent porphyria market profiled in this report.

Key Questions Answered in Global acute intermittent porphyria Market Report:

• What is the sales/revenue generated by acute intermittent porphyria across all regions during the forecast period?
• What are the opportunities in the global acute intermittent porphyria market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Acute Intermittent Porphyria Market - Research Objectives and Research Approach

The comprehensive report on the global acute intermittent porphyria market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global acute intermittent porphyria market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global acute intermittent porphyria market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Acute Intermittent Porphyria Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Acute Intermittent Porphyria Market Analysis and Forecast, 2020-2034

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product /Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Acute Intermittent Porphyria Market Analysis and Forecast, by Diagnosis

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Diagnosis, 2020-2034
  • 6.3.1. Blood Test
  • 6.3.2. Urine Test
  • 6.3.3. DNA Test
  • 6.3.4. Serum Test
• 6.4. Market Attractiveness Analysis, by Diagnosis

7. Global Acute Intermittent Porphyria Market Analysis and Forecast, by Treatment

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Treatment, 2020-2034
  • 7.3.1. Gonadotropin-Releasing Hormone Analogues
  • 7.3.2. Prophylactic Hematin Infusions
• 7.4. Market Attractiveness Analysis, by Treatment

8. Global Acute Intermittent Porphyria Market Analysis and Forecast, by End-user

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by End-user, 2020-2034
  • 8.3.1. Hospitals
  • 8.3.2. Clinics
  • 8.3.3. Research Centers
• 8.4. Market Attractiveness Analysis, by End-user

9. Global Acute Intermittent Porphyria Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region, 2020-2034
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness Analysis, by Region

10. North America Acute Intermittent Porphyria Market Analysis and Forecast

• 10.1. Introduction
• 10.2. Key Findings
• 10.3. Market Value Forecast, by Diagnosis, 2020-2034
  • 10.3.1. Blood Test
  • 10.3.2. Urine Test
  • 10.3.3. DNA Test
  • 10.3.4. Serum Test
• 10.4. Market Value Forecast, by Treatment, 2020-2034
  • 10.4.1. Gonadotropin-Releasing Hormone Analogues
  • 10.4.2. Prophylactic Hematin Infusions
• 10.5. Market Value Forecast, by End-user, 2020-2034
  • 10.5.1. Hospitals
  • 10.5.2. Clinics
  • 10.5.3. Research Centers
• 10.6. Market Value Forecast, by Country, 2020-2034
  • 10.6.1. U.S.
  • 10.6.2. Canada
• 10.7. Market Attractiveness Analysis
  • 10.7.1. By Diagnosis
  • 10.7.2. By Treatment
  • 10.7.3. By End-user
  • 10.7.4. By Country

11. Europe Acute Intermittent Porphyria Market Analysis and Forecast

• 11.1. Introduction
• 11.2. Key Findings
• 11.3. Market Value Forecast, by Diagnosis, 2020-2034
  • 11.3.1. Blood Test
  • 11.3.2. Urine Test
  • 11.3.3. DNA Test
  • 11.3.4. Serum Test
• 11.4. Market Value Forecast, by Treatment, 2020-2034
  • 11.4.1. Gonadotropin-Releasing Hormone Analogues
  • 11.4.2. Prophylactic Hematin Infusions
• 11.5. Market Value Forecast, by End-user, 2020-2034
  • 11.5.1. Hospitals
  • 11.5.2. Clinics
  • 11.5.3. Research Centers
• 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 11.6.1. Germany
  • 11.6.2. U.K.
  • 11.6.3. France
  • 11.6.4. Italy
  • 11.6.5. Spain
  • 11.6.6. Rest of Europe
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Diagnosis
  • 11.7.2. By Treatment
  • 11.7.3. By End-user
  • 11.7.4. By Country/Sub-region

12. Asia Pacific Acute Intermittent Porphyria Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Diagnosis, 2020-2034
  • 12.3.1. Blood Test
  • 12.3.2. Urine Test
  • 12.3.3. DNA Test
  • 12.3.4. Serum Test
• 12.4. Market Value Forecast, by Treatment, 2020-2034
  • 12.4.1. Gonadotropin-Releasing Hormone Analogues
  • 12.4.2. Prophylactic Hematin Infusions
• 12.5. Market Value Forecast, by End-user, 2020-2034
  • 12.5.1. Hospitals
  • 12.5.2. Clinics
  • 12.5.3. Research Centers
• 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 12.6.1. China
  • 12.6.2. Japan
  • 12.6.3. India
  • 12.6.4. Australia & New Zealand
  • 12.6.5. Rest of Asia Pacific
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Diagnosis
  • 12.7.2. By Treatment
  • 12.7.3. By End-user
  • 12.7.4. By Country/Sub-region

13. Latin America Acute Intermittent Porphyria Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Key Findings
• 13.3. Market Value Forecast, by Diagnosis, 2020-2034
  • 13.3.1. Blood Test
  • 13.3.2. Urine Test
  • 13.3.3. DNA Test
  • 13.3.4. Serum Test
• 13.4. Market Value Forecast, by Treatment, 2020-2034
  • 13.4.1. Gonadotropin-Releasing Hormone Analogues
  • 13.4.2. Prophylactic Hematin Infusions
• 13.5. Market Value Forecast, by End-user, 2020-2034
  • 13.5.1. Hospitals
  • 13.5.2. Clinics
  • 13.5.3. Research Centers
• 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 13.6.1. Brazil
  • 13.6.2. Mexico
  • 13.6.3. Rest of Latin America
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Diagnosis
  • 13.7.2. By Treatment
  • 13.7.3. By End-user
  • 13.7.4. By Country/Sub-region

14. Middle East & Africa Acute Intermittent Porphyria Market Analysis and Forecast

• 14.1. Introduction
• 14.2. Key Findings
• 14.3. Market Value Forecast, by Diagnosis, 2020-2034
  • 14.3.1. Blood Test
  • 14.3.2. Urine Test
  • 14.3.3. DNA Test
  • 14.3.4. Serum Test
• 14.4. Market Value Forecast, by Treatment, 2020-2034
  • 14.4.1. Gonadotropin-Releasing Hormone Analogues
  • 14.4.2. Prophylactic Hematin Infusions
• 14.5. Market Value Forecast, by End-user, 2020-2034
  • 14.5.1. Hospitals
  • 14.5.2. Clinics
  • 14.5.3. Research Centers
• 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 14.6.1. GCC Countries
  • 14.6.2. South Africa
  • 14.6.3. Rest of Middle East & Africa
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Diagnosis
  • 14.7.2. By Treatment
  • 14.7.3. By End-user
  • 14.7.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
• 15.2. Market Share Analysis, by Company (2023)
• 15.3. Company Profiles
  • 15.3.1. Alnylam Pharmaceuticals, Inc.
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Product Portfolio
    • 15.3.1.3. SWOT Analysis
    • 15.3.1.4. Financial Overview
    • 15.3.1.5. Strategic Overview
  • 15.3.2. Clinuvel Pharmaceuticals Ltd.
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Product Portfolio
    • 15.3.2.3. SWOT Analysis
    • 15.3.2.4. Financial Overview
    • 15.3.2.5. Strategic Overview
  • 15.3.3. BioMarin Pharmaceutical Inc.
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Product Portfolio
    • 15.3.3.3. SWOT Analysis
    • 15.3.3.4. Financial Overview
    • 15.3.3.5. Strategic Overview
  • 15.3.4. Recordati
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Product Portfolio
    • 15.3.4.3. SWOT Analysis
    • 15.3.4.4. Financial Overview
    • 15.3.4.5. Strategic Overview
  • 15.3.5. Quest Diagnostics
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Product Portfolio
    • 15.3.5.3. SWOT Analysis
    • 15.3.5.4. Financial Overview
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Invitae Corp.
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Product Portfolio
    • 15.3.6.3. SWOT Analysis
    • 15.3.6.4. Financial Overview
    • 15.3.6.5. Strategic Overview
  • 15.3.7. Laboratory Corporation of America Holdings (Labcorp)
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Product Portfolio
    • 15.3.7.3. SWOT Analysis
    • 15.3.7.4. Financial Overview
    • 15.3.7.5. Strategic Overview
  • 15.3.8. ARUP Laboratories
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Product Portfolio
    • 15.3.8.3. SWOT Analysis
    • 15.3.8.4. Financial Overview
    • 15.3.8.5. Strategic Overview

관련자료